Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
Adverum Biotechnologies Inc. (ADVM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pale Fire Capital Dusan Senkypl, David Holy, And Jan Barta | 315,154 | $1,471,769 | 0.33% | |
| 2. | Soleus Capital Guy Levy | 287,246 | $1,341,439 | 0.08% | |
| 3. | Citadel Investment Group Ken Griffin | 149,071 | $696,162 | +534% | 0% |
| 4. | Renaissance Technologies Jim Simons | 129,605 | $605,255 | +250% | 0% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 98,027 | $457,787 | +129% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.04 | 15,209 | 2,757,526 | 2025-04-02 | Filing | ||
| $4.38 | 19,566 | 2,742,317 | 2025-03-31 | Filing | ||
| $5.19 | 16,593 | 141,800 | 2025-03-27 | Filing | ||
| $5.04 | 20,407 | 125,207 | 2025-03-26 | Filing | ||
| $5.61 | 30,600 | 2,722,761 | 2025-03-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.55 | 130 | Officer | 47,674 | 2023-09-15 | Filing | |
| $1.52 | 6,071 | Officer | 47,804 | 2023-09-15 | Filing | |
| $0.78 | 7,299 | Officer | 117,435 | 2023-03-15 | Filing | |
| $0.78 | 13,360 | Officer | 265,891 | 2023-03-15 | Filing | |
| $0.78 | 41,239 | Officer, Director | 692,141 | 2023-03-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,696,815 | $6,074,597 | 5.82% | |
| 2. | 32,999 | $144,196 | 0% | |
| 3. | 100 | $437 | 0% | |
| 4. | 50 | $219 | 0% | |
| 5. | 205 | $47 | 0% |
News See All
5 Best Penny Stocks to Buy in September
Fortress Biotech, Inc. (NASDAQ:FBIO) is a New York-based company that develops and commercializes pharmaceutical and biotechnology products. On August 11, Fortress Biotech, Inc.
Hedge Fund and Insider Trading News: Ken Griffin, John Paulson, Eschler Asset Management, Satori Capital, Confluent, Inc. (CFLT), and More
A hedge fund founded and controlled by an American billionaire has increased its stake in Asos, the online fashion retailer once fêted as a stock market star.
Top 5 Stock Picks of Lawrence Kam's Sonic Capital
In this article, we will take a look at the top 5 stock picks of Lawrence Kam's Sonic Capital.
Hedge Funds Are Cashing Out Of Adverum Biotechnologies, Inc. (ADVM)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
Hedge Fund and Insider Trading News: Jaime Sterne, Kyle Bass, Alden Global, Standard General LP, Vector Group Ltd (VGR), TransDigm Group Incorporated (TDG), Carnival Corp (CCL), and More
The one-time Institutional Investor Hedge Fund Rising Star plans to close his fund to additional capital in the coming months.
Is ADVM A Good Stock To Buy According To Hedge Funds?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Adverum Biotechnologies, Inc. (ADVM) Is Stalling With Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Did Hedge Funds Make The Right Call On Adverum Biotechnologies, Inc. (ADVM) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Funds Are Betting On Adverum Biotechnologies, Inc. (ADVM)
In this article we will take a look at whether hedge funds think Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a good investment right now.
Billionaire Hedge Funds
